David M. Koelle1,2,3,4,5*
Lichun Dong1Lichen Jing1
Kerry J. Laing1
Jia Zhu2,3
Lei Jin2Stacy Selke2
Anna Wald1,2,3,6Dana Varon2
Meei-Li Huang2
Christine Johnston1,2,3
Lawrence Corey1,2,3Christine M. Posavad2,3- 1Department of Medicine, University of Washington, Seattle, WA, United States
- 2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States
- 3Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States
- 4Department of Global Health, University of Washington, Seattle, WA, United States
- 5Department of Translational Research, Benaroya Research Institute, Seattle, WA, United States
- 6Department of Epidemiology, University of Washington, Seattle, WA, United States
Antigen-specific TRM persist and protect against skin or female reproductive tract (FRT) HSV infection. As the pathogenesis of HSV differs between humans and model organisms, we focus on humans with well-characterized recurrent genital HSV-2 infection. Human CD8+ TRM persisting at sites of healed human HSV-2 lesions have an activated phenotype but it is unclear if TRM can be cultivated in vitro. We recovered HSV-specific TRM from genital skin and ectocervix biopsies, obtained after recovery from recurrent genital HSV-2, using ex vivo activation by viral antigen. Up to several percent of local T cells were HSV-reactive ex vivo. CD4 and CD8 T cell lines were up to 50% HSV-2-specific after sorting-based enrichment. CD8 TRM displayed HLA-restricted reactivity to specific HSV-2 peptides with high functional avidities. Reactivity to defined peptides persisted locally over several month and was quite subject-specific. CD4 TRM derived from biopsies, and from an extended set of cervical cytobrush specimens, also recognized diverse HSV-2 antigens and peptides. Overall we found that HSV-2-specific TRM are abundant in the FRT between episodes of recurrent genital herpes and maintain competency for expansion. Mucosal sites are accessible for clinical monitoring during immune interventions such as therapeutic vaccination.
Highlights
HSV-specific T cells persistently localize to the female reproductive tract in humans.
Female reproductive tract T cells recognize specific HSV peptides.
Female reproductive tract T cells readily expand in vitro with standard conditions.
Introduction
The majority of human T cells reside in mucosal barrier tissues outside the vasculature, and have a motility and adhesion molecule profile limiting re-entry into the circulation (1). These cells, termed tissue-resident memory (TRM) lymphocytes, are heterogeneous and include conventional T cells with hypervariable CDR3 sequences. Some innate lymphoid cells with conserved TCR variable gene usage and CDR3 amino acid (AA) domains such as mucosal-associated invariant T (MAIT) and invariant natural killer T (iNKT) cells also have memory characteristics and are included in the broad category of tissue-resident lymphocytes (2). TRM can recognize pathogens with high sensitivity and specificity. Emplacement of cells elicited by vaccination in barrier tissues is an aspirational goal for vaccines (3).
Herpes simplex virus (HSV) infection of mice provides a valuable TRM model. After recovery from primary cutaneous or female reproductive tract (FRT) infection, the natural attenuation of HSV in mice prevents ganglionic reactivation and recurrent epithelial replication. Skin and FRT TRM persist without re-exposure to antigen (4). Skin CD8+ TRM specific for an immunodominant MHC-I-restricted peptide localize to the epidermis in the region of primary infection, and mediate local protection from exogenous re-challenge. HSV-specific CD4 T cells occur mostly in the dermis after recovery from infection and are not as restricted to the site of primary infection (5, 6). In the FRT, after priming by non-lethal primary infection, protection against challenge is mediated by local CD4 T cells (7). HSV-specific CD8 T cells can also protect mice if pulled from the circulation to establish FRT TRM (3).
Human HSV TRM studies are important because HSV pathogenesis in the natural host differs from that observed in experimental animals. Acute lethality upon primary infection is only observed in persons with profound global immunodeficiency, or variations in genes most closely associated with innate immunity (8). In naïve mice, in contrast, FRT inoculation with wild-type HSV-2 is almost always fatal (9). Infected persons have periodic epithelial recurrences, with HSV-2 DNA detectable in the genital tract a median of 17% of days, in many cases without lesions or symptoms (10). These recurrences are initiated by viral reactivation in sensory ganglia, which are also a relevant local battlefield involving antigen-specific CD4 and CD8 T cells in both mice and humans (11, 12). In mice, spontaneous or even immune deficiency-triggered recurrences are very unusual and seldom progress to lytic viral replication in the periphery. Overall, periodic re-exposure to HSV antigen in humans could condition skin and FRT TRM in ways that differ from the single priming episode in murine models.
We previously found that HSV-specific CD4 and CD8 T cells can be detected in cervical specimens, even during receipt of suppressive antiviral medication (13, 14). Genital skin biopsies also revealed preferential deposition of CD8α+ cells at the DEJ of healed lesion skin compared to normal skin. Laser capture microdissection (LCM) and immunohistology showed that these cells had low chemokine receptor and mobility-associated mRNA expression and expressed cytolytic and antiviral cytokine transcripts (15). Some DEJ CD8α+ cells stained in situ with fluorescent multimer reagents comprised of HSV peptides and subject-matched HLA class I, identifying them as antigen-specific CD8+ TRM. TRCB CDR3 sequences from LCM-captured DEJ CD8α+ cells from serial biopsies over several years revealed persistent oligoclonal expansions consistent with the localization of clonally expanded TRM (15). In the present report, we build on these previous findings by more precisely measuring the frequency of HSV-2-reactive CD4 and CD8 T cells directly ex vivo in FRT specimens obtained at times when HSV is absent, and by determining their antigenic breadth and fine specificity.
Attempts to boost local T cells by therapeutic vaccination of humans have had measurable clinical success as quantified by reduction in genital lesions and HSV shedding (16, 17). However, it is not known if the bivalent approach used, containing two of the more than 75 proteins in the HSV-2 genome, contains the optimal viral antigens. Strategies to determine T cell specificity from minute biological specimens typically rely on in vitro expansion prior to interrogation of the relevant proteome (18). The complex HSV-2 genome and HLA diversity, present challenges to both in situ or direct ex vivo approaches as well as interrogation of T cell lines after expansion. Some data indicate that TRM can proliferate in vivo (19), but the capacity of these cells to expand in vitro for detailed studies is poorly understood, as TRM have specific metabolic and cytokine requirements (20). For example, lipids are important for human skin TRM energy metabolism (21). To explore the hypothesis that some HSV-specific TRM can expand in vitro, we started with a dendritic cell (DC)-based activation-induced marker (AIM) step to both measure and enrich virus-reactive skin T cells, based on a method used for blood (18). TRM were then interrogated for fine specificity with HSV genome-wide tools tailored to CD8 and CD4 T cell phenotypes.
Materials and Methods
Subjects and Specimens
Women seropositive for HSV-2 with a history of genital herpes were enrolled at the University of Washington Virology Research Clinic (VRC). Participants reported the number of annual genital herpes recurrences and the time of their most recent recurrence. Most participants collected anogenital swabs daily for at least 30 days for HSV detection by PCR (10) to measure HSV shedding rate. Serum antibodies to HSV-1 and HSV-2 were detected by immunoblot (22). Peripheral blood mononuclear cells (PBMC) were cryopreserved (23). Skin biopsies (3 mm) at sites of previous genital HSV-2 recurrence were performed as described (24). A speculum was used to visualize the cervix. Biopsies of the ectocervix were performed using a Baby Tischler forceps. Up to 3 biopsies were obtained at a single visit. Biopsies were digested with pre-warmed Collagenase Digestion Medium with DNAse I (Sigma Aldrich) at 37°C for 30 minutes. HLA typing (Supplementary Table 1) was performed at Bloodworks Northwest or Scisco (both Seattle, WA) using PCR or sequencing-based methods (25).
A cohort of six additional HSV-2 infected, immunocompetent women was recruited to provide cervical cytobrush samples and PBMC as previously described (14, 26). Specimens were negative for HSV DNA on the day of collection. Characteristics of participants donating cytobrush specimens are reported in Supplementary Table 2.
AIM Enrichment of HSV-2-Reactive Biopsy T Cell Lines
In vitro incubations were performed in humidified 5% CO2 at 37°C. Autologous monocyte-origin dendritic cells (moDC) were initiated from PBMC 6 days pre-biopsy as described (18). The protocol uses the ability of moDC to cross-present complex antigen to CD8 T cells and to simultaneously process and present complex antigen to CD4 T cells. HeLa cells (ATCC, Manassas, VA CCL-2) were infected with HSV-2 333 (Genbank KP192856.1) deleted of gene UL41 (J. Blaho, City University of New York) at MOI 2.5 for 18 hours. The protein product of UL41 has immune evasion effects on dendritic cells (27, 28). Infected or mock HeLa recovered with PBS-2 mM EDTA were treated as described with ultraviolet-C light (18). DC were seeded at 2 X 105 cells/well in 48-well plates, to which an equal number of HeLa cells were added in a total of 300 μl T cell medium (TCM) (29). After five hours for processing of HeLa cell-based antigen by moDC, biopsy digest cells were added for a final volume of 600 μl. In a separate well, biopsy-derived cells were added to moDC that were not pre-loaded with HeLa-cell based antigen, with 1.6 μg/ml PHA (Remel, Lenexa, KS) used as a positive control stimulus. After 18-20 hours, cells were recovered and stained with 7-AAD viability marker, anti-CD3-energy coupled dye (ECD) (Beckman Coulter IM2705U), anti-CD4-allophycocyanin cyanine-7 (allophycocyanin-Cy7) (Biolegend 344616), and anti-CD8-FITC (Life Technology MHCD08014). Anti-CD137-allophycocyanin (BD 550890) was used to detect T cell activation (30). Live, CD3(+)/CD4(+)/CD8(–) or CD3(+)/CD4(–)/CD8(+) cells that were CD137(+) were bulk-sorted (FACSAria III, BD).
CD137high cells were initially polyclonally expanded with PHA, feeder cells, and human natural IL-2 as described (31). Feeder cells assist T cell expansion when a non-specific mitogen is used to stimulate cell division (32). After ~ 14 days, cells were cryopreserved, or if reagents were ready (below), functionally tested and re-expanded. Polyclonal re-expansion used anti-CD3, feeder cells, and rIL-2 (33). As an alternative FRT specimen, cervical cytobrush-derived T cells (13) were recovered as previously described (14) and bulk-expanded using anti-CD3, cytokines and feeder cells (29) with neither AIM enrichment ex vivo nor in vitro exposure to HSV antigen. The rationale for non-specific T cell expansion was provision of enough FRT T cells to conduct proteome-wide determination of specificity.
T Cell Functional Assays
For CD8 T cell lines (TCL), intracellular cytokine staining (ICS) assays were used for initial measurement of specific recognition of whole HSV-2. TCL and autologous EBV-LCL were plated at 5 X 105 each in 96-well U bottom plates. EBV-LCL were uninfected or pre-infected with HSV-2 strain 186 (Genbank JX112656.1) at MOI 2.5 for 24 hours. Co-stimulatory anti-CD28 and anti-CD49d mAb were added immediately, and Brefeldin A was added at 2 hours (34). While it was possible that some EBV-specific T cells might be present in the cultures, we included non-infected EBV-LCL as a negative control to check for this. The re-expansion of TCL described above was not done after TCL exposed to HSV-2-infected EBV-LCL, but was done on non-manipulated cells after their initial CD137-based selection and expansion, such that amplification of EBV-specific T cells was avoided. After 18 hours, were cells stained with Fixable Live/Dead Near IR (ThermoFisher), treated sequentially with FACS Lyse and Permeabilization 2 (BD), stained with pooled antibodies to CD3-ECD, CD4-PE (Biolegend), CD8-FITC, IL-2-allophycocyanin (BD), and IFN-γ-PE-Cy7 (BD), washed and analyzed (Canto RUO, BD). PHA was used as positive control. Percentages of live, CD3(+)/CD8(+)/CD4(-) T cells expressing IFN-γ, IL-2, or both was recorded. Functional measurement of biopsy-derived CD4 TCL reactivity with whole HSV-2 used similar ICS conditions, tailored for CD4 T cells using autologous PBMC as APC and inactivated HSV-2 as antigen. Monocytes in PBMC can internalize and process killed HSV-2 for presentation to CD4 T cells (35). PBMC used as APC were pre-labeled with Cell Tracker Violet™ (CTV, ThermoFisher) to allow de-gating during ICS. PBMC and CD4 TCL were co-incubated at ~ 5 X 105 each in 200 μl TCM. Antigens included UV-treated HSV-2 186-infected or mock UV-treated Vero cell lysates (1:100), and PHA positive control. Analysis gated on live CTV(-)/CD3(+)/CD4(+)/CD8(-) T cells for expression of IFN-γ, IL-2, or both.
HSV-2 Specificity
Published methods (18) previously used to determine antigenic HSV-1 open reading frame(s) (ORFs) and peptide epitopes were modified for HSV-2. Each HSV-2 ORF from HSV-2 186 (Genbank JX112656.1) was PCR-cloned into a Gateway™ donor vector (Invitrogen) and shuttled using Gateway Clonase™ reactions into pDEST203 and expressed by in vitro transcription/translation (IVTT) for CD4 T cell studies. HSV-2 PCR primers, clone identities, and clone shuttling strategies are published (36). For CD8 T cell work, the same HSV-2 ORFs in donor vectors were shuttled into pDEST103 (18). Long HSV-2 ORFs cloned as fragments (36) included UL19, encoding major capsid protein VP5, and RS1, encoding infected cell protein 4 (ICP4), which were expressed as two and three overlapping fragments, respectively (36).
To screen biopsy-derived TCL for protein-level CD4 T cell responses, responder cells and autologous irradiated PBMC as APC (105/well each), and IVTT proteins at 1:2000 were incubated in duplicate in 200 μl TCM for 3 days. Negative controls were P. falciparum, F. tularensis, or vaccinia virus (VV) proteins (37, 38), empty pDEST203 vector IVTT products, IVTT reaction mix without plasmid, UV-mock virus, and media. Positive controls were PHA and UV-treated HSV-2-infected Vero cell lysate. Proliferation was assessed by 3H thymidine incorporation (24). The statistical cutoff used to establish positive reactivity has been described (39). To screen bulk cervical cytobrush-derived T cells for CD4 T cell responses, duplicate lymphoproliferation assays in 96-well U bottom plates contained 105 each cervical T cell responders, autologous gamma-irradiated PBMC, and antigens in 200 μl TCM. Each HSV-2 gene or fragment expressed by IVTT was added at 1:1000 together, with negative controls and PHA-P (1.6 μg/ml) as positive control. Proliferation assays were performed as for biopsy-derived TCL.
To screen biopsy-derived TCL for CD8 T cell responses, participant-specific HLA A and B cDNA alleles (Supplementary Table 1) were PCR-amplified and then cloned into pCDNA3.1 as described (33). HLA sequences were confirmed as correct using BLAST comparison to sequences in the IMGT database (40). Only the HLA alleles matching individual participants were used in functional screens. Artificial APC (aAPC) were created by simultaneously transfecting Cos-7 cells in 96-well flat-bottom plates with a single HLA cDNA and HSV-2 ORFs cloned into pDEST 103 (18). Each ORF-HLA combination was tested in duplicate. Polyclonal CD8 TCL were tested at 5 X 104 cells/well two days after HLA/HSV-2 gene co-transfection. Supernatants were tested for IFN-γ secretion by ELISA at 48 hours (33).
Peptide-Level Specificity
Once CD4 T cell reactivity was detected, overlapping peptides (OLP) (Genscript, or New England Peptide, Gardner, MA, 70% purity) covering the relevant ORF were tested. Some OLP are published (41). Peptides were dissolved and stored at 10-20 mg/ml in DMSO. Peptides were 13 to 15 AA overlapping by 9-11 AA (41), pooled at up to 20 peptides/pool as matrix pools (42), and tested at final concentrations of 1 μg/ml each. Assays used 5-10 X 104 TCL and 5-10 X 104 autologous irradiated (8000 rad) EBV-LCL/well as APC (42). Single peptides at the intersection(s) of reactive row and column pools that gave positive responses were tested with the same responder cells and APC. T cell activation was determined using 3H thymidine proliferation, secreted IFN-γ, or IFN-γ/IL-2 ICS as described (18).
For CD8 T cell fine specificity, OLP were also tested as matrix pools followed by decoding to single peptides. Autologous EBV-LCL and bulk CD8 T cells (105/well each) were admixed with peptide pools or single peptides (1 μg/ml each peptide) in 96-well U bottom plates in 200 μl TCM overnight and supernatants assayed for IFN-γ. As an alternative to OLP, predictive algorithms for the relevant HSV-2 ORF and HLA allele (43) were consulted and peptides with high predicted HLA binding affinity were synthesized (Genscript). Single peptides from reactive pools or algorithmic prediction were tested using IFN-γ ELISA or ICS (18).
Results
Six HSV-2 seropositive women with a median age or 43 (range, 38 to 62) with a history of recurrent genital herpes were enrolled in a prospective biopsy protocol (Table 1). Participants had clinical histories of genital HSV for a median of 19 years prior to specimen collection (range, 1 to 33 years). The median annual number of self-reported recurrences of genital herpes was 2 (range, 1-6), typical for immune competent persons (10). Each participant collected daily genital swab specimens for shedding studies as described (10) and each swab was used for HSV-specific DNA PCR. The median viral DNA detection rate of 22.3% (range, 4.4% to 55.7%) was similar to the median rate of 17% of days determined from large natural history studies (44). Genital swabs at six of the eight times of specimen collection were negative for HSV DNA by PCR, with data not available at two times of biopsy specimen collection.
Table 1 Characteristic of participants and specimens.
Healed Genital HSV-2 Skin and Ectocervix Contain Culture-Expandable HSV-2-Reactive T Cells
Cells from enzymatically digested biopsies were co-cultured with autologous blood-derived, monocyte-origin DC (moDC) that were loaded with whole HSV-2 antigen in the form of infected, UV-treated HeLa cells. The protocol allows antigen uptake, processing and cross-presentation to CD8 T cells, as shown in our work on HSV-1 and vaccinia (18). The HSV-2 strain used to antigen-load moDC lacks vhs, a protein that inhibits DC function (28). Data from the June biopsy from a representative sample from participant 15018 show a minority (3.52%) of cervical cells were CD3(+) T cells (Figure 1A). A discrete population of CD4 T cells expressed the activation marker CD137 (also called 4-1BB and TNFRSF9) after 18 hours exposure to HSV-2-loaded DC, with much lower responses to mock-loaded DC (Figure 1B). Similarly, specific activation of CD8 T cells was noted (Figure 1C). Similar trends were noted for the majority of FRT specimens (Table 2). Activated cells were expanded with non-specific mitogens. Overall, 29 biopsy-derived T cell lines derived were studied, including paired CD4 and CD8 T cell lines from 7 genital skin biopsies, and 8 CD8 and 7 CD4 cervix-derived T cell lines (Table 2). Up to 12% of CD4 T cells and 20.5% of CD8 T cells were HSV-2-reactive (subject 15018, initial cervical biopsy, Table 2). Even if analytical flow cytometry did not show net HSV-2-specific CD137 expression response for either or both T cell subsets, CD137high CD4 or CD8 T cells were isolated for downstream studies.
Figure 1 Sorting data for cervical T cells from subject 15018 initial cervix biopsy. (A) Gating scheme. (B, C) Gated CD8 and CD4 T cells stained for CD137 expression after exposure to HSV-2- or mock-loaded autologous moDC. Gates show cells selected for sorting as CD137high. Percentages are proportion of cells in dotplots within CD137high gates.
Table 2 Activation of FRT biopsy-derived T cells after exposure to HSV-2-loaded autologous moDC.
Activated CD137high CD4 or CD8 T cells sorted from HSV-2-stimulated conditions were polyclonally expanded and the reactivity of the resultant bulk TCL measured using appropriate APC. Experiments to document enrichment of HSV-2-reactive CD4 T cells within the CD137high-origin CD4 TCL used autologous PBMC as APC, whole viral antigen, and IFN-γ/IL-2 ICS as readout. Marked enrichment was noted (representative data in Figure 2A). Both IFN-γ and IL-2 were strongly positive. Similar enrichment measurement was performed for biopsy-derived CD8 TCL. HSV-2-infected EBV-transformed B lymphocytes (EBV-LCL) were used as APC to allow for endogenous antigen processing and presentation. While B lymphocytes are not targets of HSV infection in vivo (45), EBV-LCL are permissive for lytic HSV replication in vitro (46) and are recognized by CD8 HSV-2-specific T cells (31). Specific recognition of whole HSV-2 resulted in high frequencies of IFN-γ-expressing CD8 T cells. IL-2 also detectable (Figure 2B) but at levels lower than for CD4 T cells.
Figure 2 Responses of bulk-expanded, AIM-selected TCL from subject 15018 June cervix biopsy. (A) CD4 T cells. Top row shows gating scheme. Autologous PBMC used as APC were dump-gated by prior labeling with CTV. Lower row has gated CD4 T cells analyzed by ICS for accumulation of IFN-γ and IL-2 with the labeled stimuli. Specific responses are present to autologous PBMC treated with UV-HSV-2 antigen for CD4 responder cells. (B) CD8 T cells. Upper row has gating scheme. EBV-LCL used as APC are CD3-negative and did not require dump gating. Lower row shows responses to autologous EBV-LCL infected with HSV-2 or mock virus, and control stimuli. Numbers are percentages of gated cells.
Biopsy-Derived TRM Recognize Discrete HSV-2 Antigens and Epitopes
Virus-specific cytokine responses to whole HSV-2 by polyclonal FRT biopsy-derived TCL suggested the presence of reactivity to detect discrete viral proteins and internal peptides, and restriction by autologous HLA alleles. To study this, CD8- and CD4-specific methods from HSV-1 research (11, 18) were adapted for proteome-wide screens of HSV-2. For CD8 T cells, panels of artificial APC (aAPC) were created using Cos-7 cells, a well-established procedure in which the non-human primate Cos-7 provide a compatible β2-microglobulin partner for HLA class I (47). The aAPC were co-transfected with HLA and a panel of plasmids encoding each HSV-2 gene. A representative CD8 TCL from participant 15018 for one exemplar HLA allele, HLA A*03:01, show recognition of the HSV-2 RS1-encoded protein ICP4, as well as the N-terminal fragment of the UL19-encoded major capsid protein VP5 (Figure 3A) using an IFN-γ readout, with negligible background responses. The same TCL showed HLA A*32:01-restricted recognition of the C-terminal portion of VP5, HLA B*07:02-restricted recognition of VP22 (encoded by UL49), and HLA B*44:02-restricted recognition of the UL6-encoded capsid portal protein and the UL23-encoded thymidine kinase. Overall, results from screens of each subject-specific HLA A and B allele show that the TCL from this cervical biopsy recognized 6 separate HSV-2 proteins (Figure 3B). To determine if TRM persisted over time, we obtained cervical biopsy from this participant 3 months later (Figure 3B). UL49 and UL23-specifc responses with the same HLA restriction were again noted. A new specificity (HLA B*07:02-restricted reactivity to UL46-encoded tegument protein VP11/12) was detected at the later time point.
Figure 3 CD8 T cell recognition of HSV-2 antigens by AIM-enriched cervical biopsy-derived TRM from subject 15018. (A) Representative duplicate data for June biopsy. Rightmost bars are negative controls (empty vector plus HLA, HLA alone). aAPC express HLA A*03:01, a single subject-specific HLA class I allele and individual HSV-2 genes or fragments (B) Heat map of reactivity with duplicate assays for subject HLA (A, B) Responder cells were derived from June (Jun) and September (Sep) biopsies. Reactive HSV-2 genes are labeled. Negative control stimuli in bottom two rows. Screens for each subjects-specific HLA A and B allele (A*03:01, A*32:01, B*07:02, and B*44:02) are shown separately with the intensity of IFN-γ expression indicated per the graphic scale. (C) CD8 T cell epitope discovery using predicted HLA -binding peptides. TCL from June biopsy assayed with 1 μg/ml indicated UL6 peptides and autologous LCL as APC. (D) OLP pathway for epitope discovery. TCL from same biopsy stimulated with matrix row (RP) and column (CP) pools of 10 to 20 15 AA-long peptides/pool spanning the reactive UL19 AA 1-703 fragment at 1 μg/ml each peptide. At right, results for 1 μg/ml peptide at the intersection of RP11 and CP8 pools. Colored dots are duplicate raw data and gray bar is mean.
Following antigen identification, internal discrete CD8 T cell epitopes were documented for selected TCL and HLA cDNA/HSV-2 ORF combinations. In some cases, assays focused on peptides in reactive HSV-2 ORFs predicted to bind relevant HLA alleles (representative data, Figure 3C). In other cases, ORF-covering OLP sets were tested, typically as matrix pools followed by single reactive peptides (representative data, Figure 3D). Additional examples of CD8 TRM HSV-2 peptide epitope discovery (Supplementary Figure 1) show high signal-to-noise ratios and discrete recognition of single peptides. We note that for CD8 and CD4 workflows (below), the discovery of discrete epitopes within “hit” HSV-2 ORFs serves functionally as validation of T cell reactivity with the ORF in question, contributing to rigor and reproducibility. Further confirmation of accurate identification of antigenic specificity is afforded by peptide dose-response analyses (also below) in which reactivity with peptides within HSV-2 ORFS is repeatedly observed.
The AIM-enriched biopsy CD4 TCL were similarly tested using a proteome-covering panel of recombinant HSV-2 proteins (36). Given the requirement for antigen uptake, processing and presentation to CD4 T cells, autologous PBMC were used as APC. A cell proliferation assay optimized in our previous viral proteome-wide screens (18, 48, 49) was used in place of IFN-γ secretion, albeit we have also used IFN-γ secretion to probe T cell responses to protein panels from microbial genomes (38). CD4 TRM reactivity with individual HSV-2 proteins was frequently detected. Representative data from the skin biopsy of participant 9149 (Figure 4A) showed reactivity for at least four HSV-2 proteins: UL1-encoded glycoprotein L, the UL19 major capsid protein, the UL29 DNA binding protein, and the UL36 large tegument protein.
Figure 4 HSV-2 FRT CD4 T cell antigen and epitope discovery using culture-expanded TRM. (A) Screen of skin biopsy-derived TCL from subject 9149 against HSV-2 proteome in duplicate proliferation assay. Gene and short protein names of antigenic proteins are shown; negative control mock virus and positive control whole UV-killed HSV-2 and PHA at right. (B) Peptide epitope workup for cervix-derived TCL from subject 9149. OLP from HSV-2 gD (gene US6, 15AA long, left) or HSV-2 VP22 (gene UL49, 13 AA long, right) were arrayed in row (RP) and column (CP) pools with 1 μg/ml each peptide. Peptides from the intersection (UL6) or intersections (UL49) of reactive pools were re-assayed at 1 μg/ml at right of each diagram. APC were autologous irradiated PBMC. Colored dots are duplicate raw data and gray bar is mean.
We separately measured HSV-2 antigen-level specificity of a cervical cytobrush-derived bulk TCL. With these specimens, HSV-2-reactive cells were not enriched ex vivo by antigen re-exposure or selection in vitro. Two participants (9149, 15018, Table 1) overlapped with the biopsy cohort and an additional 6 persons were also studied (Supplementary Table 2). Discrete responses to individual HSV-2 proteins were frequently detected (representative data, Supplementary Figure 2A). These responses are presumed to be due to CD4 T cells as presentation of IVTT-expressed proteins by APC in unmanipulated PBMC to CD8 T cells is unlikely. Overall, at least one HSV-2 protein was recognized in all 14 cytobrush samples from each participant (Supplementary Figure 2B). Across the specimen set, 34 of the 71 HSV-2 proteins were antigenic in one or more samples. Within-participant consistency was noted for reactivity to some HSV-2 proteins; for example, participant 13931 recognized HSV-2 proteins UL23, UL39, and UL46 in each of 3 cytobrush specimens collected over 263 days. These results extend previous HSV-2 genomic library and peptidome surveys (26, 35) and indicate that both deeper biopsies of cervical tissue and superficial cells accessible to cytobrush scraping are rich in HSV-2-specific CD4 T cells.
Once reactive HSV-2 ORFs were identified, specific CD4 T cell epitopes were determined using OLP approaches as for CD8 T cells, above. Representative data for the cervix-derived TCL from participant 9149 (Figure 4B, left) shows an example from US6 (encodes glycoprotein D) in which single matrix pools were reactive. The peptide nominated by the pool approach, gD AA 201-215, was confirmed as reactive in a follow-up assay. Other matrix results were more complex. In an example for the same TCL and HSV-2 UL49, column pool 1 and both row pools 1 and 2 were reactive. The 13 AA peptides UL49 45-57 and UL49 49-61, at the respective intersections of these pools, were each antigenic. As expected, the 9 AA peptide UL49 AA 49-57, at the overlap of the antigenic 13 AA peptides, was also recognized by the TCL (Figure 4B, right). For CD4 TCL from subject 9149, IFN-γ ICS epitope mapping using peptide pools agreed quite well with pool-level and follow-up single peptide proliferation assays (Supplementary Figure 3). IFN-γ ICS was also used for the same participant to confirm fine peptide specificity after initial pool-level mapping using proliferation assays (Supplementary Figure 4).
CD8 TRM Functional Avidity
Following peptide epitope identification, the functional avidity of culture-expanded, polyclonal CD8 TRM was evaluated using peptide titration. We concentrated on the serial cervical biopsies from subject 15018, studying T cells specific for every HSV-2 antigen/HLA combination detected as antigenic in screens of HLA/HSV-2 gene co-transfected aAPC (Figure 3). CD8 TRM could show very high functional avidity (Figure 5). For example, UL49 AA 49-57-specific CD8 TRM from cervical biopsies separated by 3 months had estimated EC50 values below 1 picogram/ml peptide. Response potency was typically higher than those observed for HSV-2 CD8 T cell clones from active HSV-2 lesions (33), derived from PBMC by tetramer sorting (50) or obtained from blood by leveraging the high, specific cutaneous leukocyte antigen (CLA) expression programmed into circulating memory HSV-2-specific CD8 T cells (51, 52). Remarkably, the same 9 amino acid peptide, UL49 AA 49-57, was potently recognized by both CD8 (Figure 5) and CD4 T cells (Figure 4B), albeit from separate participants.
Figure 5 Functional avidity of human FRT-derived HSV-2-specific polyclonal CD8 TRM from subject 15018 cervical biopsies from June (top rows) or September (lower row) samples. TCL were incubated with autologous EBV-LCL and dilutions of peptide. Insets list HSV-2 gene, AA numbers and sequence of peptide tested, and HLA restriction of epitope. T cell activation was measured by supernatant IFN-γ ELISA. Colored dots are duplicate raw data and gray bar is mean. Note varied X and Y axes. Some peptides were tested over an expanded concentration range. DSMO negative control <0.06 OD450 for all assays.
Discussion
This report focuses on the human FRT as an interface between HSV and the acquired immune response. For the cervix, we used a combination of biopsies and cytobrush samples to study both deeper and more superficial local T cell responses to this pathogen. In the context of intermittent HSV-2 antigen exposure in the natural host, we find that HSV-2-specific CD8 and CD4 T cells are abundant, retain the ability to recognize antigen by up-regulating activation markers ex vivo, and briskly proliferate in vitro. A broad spectrum of viral antigens and epitopes are recognized, often with high functional avidity.
The work in this report indicates that TRM can recognize a relatively wide array of HSV-2 antigens. CD8 T cell antigens recognized by the skin and FRT-derived T cells in this report ranged from transcription factors (ICP4 encoded by RS1) expressed immediately after lytic replication starts, to abundant structural proteins such as the major capsid protein VP1 encoded by UL19, expressed late in the viral life cycle. The spectrum of CD4 T cell antigens was also quite wide, especially when the cervical cytobrush-derived T cells are included. We have previously detected HSV-2-specific CD8 T cells in cytobrush specimens (53) and proteome-wide tools could be applied to extend specificity determination to these samples. Within-subject diversity is hard to estimate given the limited anatomic samples we can access, but it is remarkable that up to six discrete CD8 T cell epitopes could be detected within a cervical biopsy as for subject 15018, and up to 14 HSV-2 antigens were recognized by CD4 T cells from a cervical cytobrush from subject 13931. Previously, we resorted to T cell cloning from biopsies or cytobrush samples and typically used traditional genomic HSV-2 DNA molecular libraries to discovery the fine specificity of tissue-derived HSV-specific T cells (33, 35, 54). Throughput is greatly enhanced using polyclonal TCL and virtual libraries of HSV ORFs, at the possible expense of missing rare responses. Previous measures of blood or tissue T cell epitope diversity for HSV-1 and HSV-2 indicated recognition of 20 or fewer epitopes/specimen (18, 37, 55, 56), fairly close to our current data.
Our co-transfection workflow determines HLA restriction in parallel to antigenic specificity for CD8 T cells. For CD4 T cells, established pathways for determining restricting HLA loci and alleles (57) are available. For HSV-2 UL49 AA 49-57, a known HLA B*07:02 restricted CD8 T cell epitopes we also noted recognition by CD4 T cells for subject 9149 (Figure 4). Submission of the HSV-2 sequence to algorithms (43) for the relevant subject’s HLA class I and II alleles does not reveal any internal peptide sequence/allele combinations with high predicted binding affinity.
Related to specificity and phenotype, virus-specific CD4 and CD8 T cells may function optimally in close proximity to one another. For example, we observed that culture-expanded CD8 TRM expressed minimal IL-2 while CD4 T cells expressed this cytokine in abundance (Figure 2B). Our work disclosed coordinated local CD4 and CD8 virus-specific T cell responses in many specimens. Other properties, such as the affinity of TRM TCRs for peptide-HLA, could also be vital, with the reasonable hypothesis that high TRM affinity would lead to earlier detection of pathogen and thus better control. Affinity requires biochemical assays to measure, but can be approximated by functional avidity, as in this report. We observed quite high functional avidity for polyclonal TCL specific for peptides in the tegument proteins encoded by UL46 and UL49 (Figure 5), with strong recognition of 1 pg/ml viral peptide. It is likely that the epitope-specific response is heterogeneous at the TCR clonotype level, as we observed in studies of T cells specific for a tumor virus (58), and that functional affinities vary with TCR sequence. In a murine HSV model with localization of virus-specific CD8 T cells to latently infected ganglia, ganglionic TRM had higher functional avidity than T cells specific for the same HSV epitope found in the lung, a non-infected site (59). In a murine model of cleared vaccinia infection, functional avidity varied between intestinal CD8 TRM specific between intraepithelial and lamina propria layers (60). Future work will be required to determine if there is a hierarchy of functional avidity between blood and tissue compartments. While we did not study enough subjects to suggest nominating a specific HSV-2 ORF as vaccine candidate, it should be noted that chimeric multi—partial ORF and multi-epitope vaccines are increasingly entering clinical trials for both infection and cancer, including tuberculosis and melanoma (61, 62) and COVID-19 (clinicaltrials.gov NCT04776317). HSV epitope knowledge from the present and prior genital tissue-based studies ((63) combined with blood and neuronal ganglia studies (11) could allow a similar customized antigen to design a T cell-directed HSV vaccine immunogen.
Our studies suggest that the lymphocytic infiltrate seen after HSV infection is comprised at least in part by antigen-specific cells. After recovery from attenuated HSV infection, memory lymphoid clusters containing HSV-reactive CD4 T cells occur submucosally in murine FRT (7) and skin (64). In humans, a leukocytic infiltrate occurs in the endocervix in response to HSV (65), and CD4 and CD8 T cells infiltrate the dermis during and after infection (66). Less is known about the ectocervix. HSV-2 antigen remains in the epithelium regardless of anatomic location in skin vs. mucosal surfaces, and does not penetrate the basement membrane in the immunocompetent host (66). Recently, a plasma cell infiltrate in acute and healed HSV-2 genital skin lesions and local HSV-specific IgG have been reported (67). While the fine specificity of the local B lymphocytes is not yet known, it is possible that local antigen-specific T cells cooperate with B lymphocytes for antibody production
These studies are motivated by the unmet need for preventative and therapeutic HSV vaccines. Therapeutic and preventative vaccine clinical trials have used HSV-2-based candidates ranging in complexity from peptides to whole virus (68). Partial success has been demonstrated with preventative vaccine candidates that trigger CD4 T cells and antibody in humans (69–72), and data that passive antibody transfer can protect mice in an FcR-dependent manner against genital HSV-2 challenge (73, 74) has led to renewed interest in antibody-based vaccine prevention. The success of recombinant zoster vaccine (RZV) for recurrent infection by varicella zoster virus (VZV), a pathogen that shares tropism, sequence, and T cell epitopes with HSV (34), has re-invigorated therapeutic HSV vaccine efforts as well. In this regard, a bivalent gD2/ICP4 HSV-2 protein-based candidate showed efficacy as measured by genital HSV shedding and lesion rates (16, 17). The mechanisms of action of RZV and gD2/ICP4 remain unknown but are presumed to involve antibodies and/or CD4 T cells (75–78). To date, prevalent, durable, and quantitatively significant boosts of CD8 T cells have not been demonstrated in human HSV vaccine immunotherapy trials. We and others (79) hypothesize that HSV-2-specific CD4 and CD8 T cells at the site of recurrent infection are important for containing virus, and that ultimately, boosting the levels or enhancing the phenotype of peripheral virus-specific T cells could lead to clinical and virologic reduction of recurrence infection.
Human studies, while challenging, are of interest because HSV pathogenesis varies greatly between species. Non-human primates range from hyper-susceptible (80) to mostly resistant (81). Outbred rats (82), guinea pigs (83), and rabbits (84) can recover and have recurrences, but immunologic tools are limited. Inbred mice differ for HSV susceptibility per genetic background (85) and require hormonal treatment for primary FRT infection (86). Surviving animals have a coordinated humoral, CD4 and CD8 T cell response. HSV-specific TRM are readily observed in the skin, FRT, and sensory ganglia in mice. Sophisticated tools allow precise localization, quantitation, expression profiling, and live cell monitoring during immune surveillance (87–90). However, HSV does not recur to the level of peripheral culture-positive viral reactivation outside of profound epigenetic manipulations (91). Therefore, explant, re-infection, and parabiosis models are used to study TRM functionality. In contrast, HSV reactivates in essentially all infected persons (10). For immune competent persons with antibodies to HSV-2 and a clinical history of genital herpes, the population studied in this report, viral DNA is detected in anogenital swabs by PCR on a median of 17-20% of days (10).
The properties associated with effective control of recurrent HSV infection by TRM are unknown. Mathematical models indicate that TRM density threshold may be critical to determining if the outcome of neuronal delivery of HSV from axon termini is a brief period of low level viral shedding or exponential growth of virus in a clinically evident recurrent lesion episode (92). Cytokine released by TRM such as IFN-γ are thought to mediate paracrine effects to induce a net anti-viral state in the vicinity (93). Localization near sites of HSV replication may also be critical. Our human in situ work has stained occasional CD8 T cells at the dermo-epidermal junction (DEJ) in skin biopsies from sites of previous HSV recurrences with HSV-specific peptide-HLA reagents (15).
This study has several limitations. We used moDC as APC because of their ability to cross-present to CD8 T cells and to also process and present antigen to CD4 T cells. Discrete DC subsets prime CD8 and CD4 T cells in murine HSV models (94, 95) and human moDC can present HSV antigen (96), but further research is required to determine the importance of DC in the context of human recurrent HSV infection. We used a strain of HSV-2 deleted in UL41 to re-stimulate HSV-2-specific T cells ex vivo, such that T cell responses to the protein product of UL41 would be missed. UL41 encodes an RNAse with complex influences on HSV replication, pathogenesis and immune evasion (97–100); biases in the spectrum of T cells recalled by presentation of UL41-deleted HeLa cells are therefore possible. The UL41 deletant is based on HSV-2 strain 333. This has a small number of predicted amino acid changes from HSV-2 strain 186 used for whole virus readouts and as the source for HSV-2 proteins. Each subject was infected with yet a 3rd strain of HSV-2 that could also vary in amino acid sequence, possibly contributing to strain-specific responses (101). Overall, however, coding differences between HSV-2 strains are relatively minor (102, 103).
In addition, we studied a limited number of subjects and supplemented biopsies with cervical cytobrush specimens, a site related to, but immunologic distinct from the ectocervix. Only women were studied in this research restricted to the FRT; similar studies of male-specific tissues could be envisaged but are limited by the male genital biopsies. It could be argued that the T cells studied in this report are not challenged to persist in the periphery in the long-term absence of antigen. The tools created in the current study should enable future work to fully define the phenotype of FRT and skin HSV-specific T cells in humans, and compare and contrast them to T cells left behind by other pathogens that are permanently cleared, such as the related virus VZV. With regards to the requirement for antigen for maintenance of local virus-specific cells, we have previously shown that HSV-2-specific CD4 cells are enriched in cervical cytobrush specimens (13) and genital skin biopsies (66) during treatment with the antiviral drug acyclovir, a treatment (104) that reduces antigen.
We did not phenotype biopsy- or cytobrush-derived cells for TRM markers such as CD69 or CD103 ex vivo, and refrained from staining for these markers after T cell expansion due to uncertainty about the effect of in vitro culture on their expression. Several lines of evidence suggest the cells studied in this report are TRM. Specimens were obtained at times of negative HSV PCR, a surrogate for the absence of HSV antigen. In our previous studies comparing cervical biopsy-derived CD4 T cells with and without expression of the TRM marker CD103, a higher proportion of CD103(+) than of CD103(-) cells showed IFN-γ responses to whole HSV-2 antigen. Both the CD103(+) and CD103(-) fractions had higher IFN-γ expression than did blood CD4 T cells (14). Expression of TRM markers such as CD103 and CD69 is heterogeneous (105, 106). Recently, we reported that cervical biopsy-derived T cells obtained at times of negative HSV PCR express high levels of mRNAs encoding CD69 and the integrin subunits of CD103. Moreover, these cells have considerable TRB CDR3 overlap with blood HSV-2-specific CD8 T cells, implying that they are HSV-2-specific (107). Future studies could combine single cell phenotyping at the protein or mRNA levels with TCR sequencing and determination of virus specificity by expressing TCRs in reporter cells, a process we have piloted for blood-origin HSV-specific T cells (34). Theoretically, FRT-derived cells could be fractionated per TRM marker expression after isolation from biopsies or cytobrush specimens and prior to antigen exposure, but this would likely be technically challenging given the recovery of low cell numbers from these specimens.
It is possible that the HeLa cells used to load HSV-2 antigen into moDC could re-stimulate HPV-reactive T cells. HeLa express HPV18 E6 and E7 (108). Figure 1 is an example in which stimulation of PBMC with moDC-mock-HeLa led to non-zero, CD137-expressing CD4 and CD8 T cells, consistent with our previous publication (18). HPV-specific T cells are rare: in vitro elicitation of HPV E6 or E7-reactive T cells from PBMC uses repetitive cycles of re-stimulation with high concentrations of peptides (109), and in vivo vaccinations use many cycles of peptide-loaded DC (110). It would be possible to query our HSV-reactive T cell lines with HPV expression constructs (111) to detect HPV-specific reactivity in our system.
We did not directly compare the abundance of HSV-specific T cells in PBMC and cervical specimens from the same subjects. In a previous study comparing direct ex vivo PBMC CD137-based AIM with IFN-γ ICS, the abundance of CD8 T cells reactive with HSV-1-loaded autologous moDC was under 1% (18). In a separate study of 67 HSV-2-infected persons, including serial sampling, with ex vivo ICS to detect IFN-γ, IL-2, or TNF-α, the median net abundance of CD4 T cells expressing any one or more cytokine in response to whole killed HSV-2 was 0.56% (112). The observed high abundances of HSV-2-reactive T cells in some of our genital biopsy specimens is evidence for local quantitative enrichment, which could be reinforced by study of simultaneously collected blood and local specimens.
In conclusion, the human FRT is richly and persistently infiltrated with HSV-2-specific CD8 and CD4 T cells in immunocompetent persons with a clinical history of recurrent genital herpes. These virus-specific effectors are readily detectable at both the ectocervix and in genital skin. Responses are typically poly-specific and have high functional avidity. Ultimately, measurement of the functional importance of epithelial TRM in the control of recurrent HSV infection awaits clinical trials of vaccines capable of emplacing and increasing TRM. The technologies developed for this study should enable safe and efficient TRM assays based on clinically acceptable biopsies or cervical cytobrush specimens to be used in clinical trials of next-generation vaccines (113) being evaluated for elicitation of anatomically relevant T cell responses.
Author’s Note
Presented in part at the 42nd International Herpesvirus Workshop, Ghent, Belgium, July 2017, abstract 1.05.
Data Availability Statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Ethics Statement
The studies involving human participants were reviewed and approved by University of Washington Institutional Review Board. The patients/participants provided their written informed consent to participate in this study.
Author Contributions
DK, CP, and LC conceived the study. DK wrote the paper and created data visualizations. CJ, DV, and AW collected the specimens. LD, LCJ, LJ, JZ, CP, MH and KL optimized tissue preparations and performed experiments. SS managed data. All authors contributed to the article and approved the submitted version.
Funding
NIH grants AI030731 (DMK, CJ, AW), R01 AI042528 (JZ and LC), R01 AI134878 (JZ and LC), P30 CA015704 (core facilities), R01 AI091701 (CP), R21 AI083418 (CP), NIH contract 75N93019C00063 (DK).
Conflict of Interest
DK, CP, and LC are co-inventors of patents concerning HSV vaccines owned and managed by their institutions. DMK receives research funding from Sanofi Pasteur concerning testing samples from a clinical trial of an HSV vaccine.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
Dr. John Blaho, City College for New York, provided HSV-2 strain 333 deleted in vhs (UL41). We thank Antigen Discovery, Inc., for control plasmids encoding F. tularensis proteins. We thank the staff of the Virology Research Clinic for specimen collection, and the participants.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.867962/full#supplementary-material
Abbreviations
AIM, activation induced marker; aAPC, artificial antigen presenting cell; CLA, cutaneous leukocyte antigen; CTV, cell trace violet; Cy5, Cy7, cyanine 5, cyanine 7; DC, dendritic cell; DEJ, dermo-epidermal junction; ECD, energy coupled dye; FRT, female reproductive tract; HPV, human papillomavirus; ICP, infected cell protein; ICS, intracellular cytokine secretion; IMGT, international immunogenetics information system; iNKT, invariant natural killer T; IVTT, in vitro transcription translation; EBV-LCL, Epstein-Barr virus transformed lymphocyte continuous line; LCM, laser capture microdissection; MAIT, mucosa-associated invariant T; OLP, overlapping peptides; rIL-2, recombinant IL-2; RNAseq, RNA sequencing; TCL, T cell line; TCM, T cell medium; TCRα, TCRβ, T cell receptor alpha, T cell receptor beta polypeptides; TNFRSF9, tumor necrosis factor receptor superfamily member 9; TRA, TRB, T cell receptor alpha, T cell receptor beta genes; TRM, tissue resident memory T cell; UL, unique long region of HSV genome; VP, virion protein; vhs, virion host shutoff gene, protein encoded by HSV gene UL41.
References
1. Mackay LK, Kallies A. Transcriptional Regulation of Tissue-Resident Lymphocytes. Trends Immunol (2017) 38:94–103. doi: 10.1016/j.it.2016.11.004
2. Fan X, Rudensky AY. Hallmarks of Tissue-Resident Lymphocytes. Cell (2016) 164:1198–211. doi: 10.1016/j.cell.2016.02.048
3. Shin H, Iwasaki A. A Vaccine Strategy That Protects Against Genital Herpes by Establishing Local Memory T Cells. Nature (2012) 491:463–7. doi: 10.1038/nature11522
4. Shin H, Iwasaki A. Tissue-Resident Memory T Cells. Immunol Rev (2013) 255:165–81. doi: 10.1111/imr.12087
5. Macleod BL, Bedoui S, Hor JL, Mueller SN, Russell TA, Hollett NA, et al. Distinct APC Subtypes Drive Spatially Segregated CD4+ and CD8+ T-Cell Effector Activity During Skin Infection With HSV-1. PloS Pathog (2014) 10:e1004303. doi: 10.1371/journal.ppat.1004303
6. Gebhardt T, Whitney PG, Zaid A, Mackay LK, Brooks AG, Heath WR, et al. Different Patterns of Peripheral Migration by Memory CD4+ and CD8+ T Cells. Nature (2011) 477:216–9. doi: 10.1038/nature10339
7. Iijima N, Iwasaki A. T Cell Memory. A Local Macrophage Chemokine Network Sustains Protective Tissue-Resident Memory CD4 T Cells. Sci (New York NY) (2014) 346:93–8. doi: 10.1126/science.1257530
8. Casanova JL. Severe Infectious Diseases of Childhood as Monogenic Inborn Errors of Immunity. Proc Natl Acad Sci USA (2015) 112:E7128–37. doi: 10.1073/pnas.1521651112
9. Parr MB, Parr EL. Mucosal Immunity to Herpes Simplex Virus Type 2 Infection in the Mouse Is Impaired by In Vivo Depletion of T Lymphocytes. J Virol (1998) 72:2677–85. doi: 10.1128/JVI.72.4.2677-2685.1998
10. Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, et al. Genital Shedding of Herpes Simplex Virus Among Symptomatic and Asymptomatic Persons With HSV-2 Infection. Jama (2011) 305:1441–9. doi: 10.1001/jama.2011.420
11. van Velzen M, Jing L, Osterhaus AD, Sette A, Koelle DM, Verjans GM. Local CD4 and CD8 T-Cell Reactivity to HSV-1 Antigens Documents Broad Viral Protein Expression and Immune Competence in Latently Infected Human Trigeminal Ganglia. PloS Pathog (2013) 9:e1003547. doi: 10.1371/journal.ppat
12. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T Cells in Nonlymphoid Tissue That Provide Enhanced Local Immunity During Infection With Herpes Simplex Virus. Nat Immunol (2009) 10:524–30. doi: 10.1038/ni.1718
13. Koelle DM, Schomogyi M, Corey L. Recovery of Antigen-Specific T-Cells From the Uterine Cervix of Women With Genital Herpes Simplex Virus Type 2 Virus Infection. J Infect Dis (2000) 182:662–70. doi: 10.1086/315749
14. Posavad CM, Zhao L, Dong L, Jin L, Stevens CE, Magaret AS, et al. Enrichment of Herpes Simplex Virus Type 2 (HSV-2) Reactive Mucosal T Cells in the Human Female Genital Tract. Mucosal Immunol (2017) 10(5):1259–69. doi: 10.1038/mi.2016.118
15. Zhu J, Peng T, Johnston C, Phasouk K, Kask AS, Klock A, et al. Immune Surveillance by CD8alphaalpha+ Skin-Resident T Cells in Human Herpes Virus Infection. Nature (2013) 497:494–7. doi: 10.1038/nature12110
16. Bernstein DI, Wald A, Warren T, Fife K, Tyring S, Lee P, et al. Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial. J Infect Dis (2017) 215:856–64. doi: 10.1093/infdis/jix004
17. Bernstein DI, Flechtner JB, McNeil LK, Heineman T, Oliphant T, Tasker S, et al. Therapeutic HSV-2 Vaccine Decreases Recurrent Virus Shedding and Recurrent Genital Herpes Disease. Vaccine (2019) 37:3443–50. doi: 10.1016/j.vaccine.2019.05.009
18. Jing L, Haas J, Chong TM, Bruckner JJ, Dann GC, Dong L, et al. Herpes Simplex Virus Type 1 T-Cells Antigens in Humans Revealed by Cross-Presentation and Genome-Wide Screening. J Clin Invest (2012) 122:654–73. doi: 10.1172/JCI60556
19. Beura LK, Mitchell JS, Thompson EA, Schenkel JM, Mohammed J, Wijeyesinghe S, et al. Intravital Mucosal Imaging of CD8(+) Resident Memory T Cells Shows Tissue-Autonomous Recall Responses That Amplify Secondary Memory. Nat Immunol (2018) 19:173–82. doi: 10.1038/s41590-017-0029-3
20. Masopust D, Soerens AG. Tissue-Resident T Cells and Other Resident Leukocytes. Annu Rev Immunol (2019) 37:521–46. doi: 10.1146/annurev-immunol-042617-053214
21. Pan Y, Tian T, Park CO, Lofftus SY, Mei S, Liu X, et al. Survival of Tissue-Resident Memory T Cells Requires Exogenous Lipid Uptake and Metabolism. Nature (2017) 543:252–6. doi: 10.1038/nature21379
22. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western Blot (Immunoblot) and Glycoprotein G-Specific Immunodot Enzyme Assay for Detecting Antibodies to Herpes Simplex Virus Types 1 and 2 in Human Sera. J Clin Microbiol (1988) 26:662–7. doi: 10.1128/jcm.26.4.662-667.1988
23. Tigges MA, Koelle DM, Hartog K, Sekulovich RE, Corey L, Burke RL. Human CD8+ Herpes Simplex Virus-Specific Cytotoxic T Lymphocyte Clones Recognize Diverse Virion Protein Antigens. J Virol (1992) 66:1622–34. doi: 10.1128/jvi.66.3.1622-1634.1992
24. Koelle DM, Corey L, Burke RL, Eisenberg RJ, Cohen GH, Pichyangkura R, et al. Antigenic Specificity of Human CD4+ T Cell Clones Recovered From Recurrent Genital HSV-2 Lesions. J Virol (1994) 68:2803–10. doi: 10.1128/jvi.68.5.2803-2810.1994
25. Smith AG, Pereira S, Jaramillo A, Stoll ST, Khan FM, Berka N, et al. Comparison of Sequence-Specific Oligonucleotide Probe vs Next Generation Sequencing for HLA-A, B, C, DRB1, DRB3/B4/B5, DQA1, DQB1, DPA1, and DPB1 Typing: Toward Single-Pass High-Resolution HLA Typing in Support of Solid Organ and Hematopoietic Cell Transplant Programs. Hla (2019) 94:296–306. doi: 10.1111/tan.13619
26. Posavad CM, Zhao L, Mueller DE, Stevens CE, Huang ML, Wald A, et al. Persistence of Mucosal T-Cell Responses to Herpes Simplex Virus Type 2 in the Female Genital Tract. Mucosal Immunol (2015) 8:115–26. doi: 10.1038/mi.2014.47
27. Cotter CR, Nguyen ML, Yount JS, Lopez CB, Blaho JA, Moran TM. The Virion Host Shut-Off (Vhs) Protein Blocks a TLR-Independent Pathway of Herpes Simplex Virus Type 1 Recognition in Human and Mouse Dendritic Cells. PloS One (2010) 5:e8684. doi: 10.1371/journal.pone.0008684
28. Cotter CR, Kim WK, Nguyen ML, Yount JS, Lopez CB, Blaho JA, et al. The Virion Host Shutoff Protein of Herpes Simplex Virus 1 Blocks the Replication-Independent Activation of NF-kappaB in Dendritic Cells in the Absence of Type I Interferon Signaling. J Virol (2011) 85:12662–72. doi: 10.1128/JVI.05557-11
29. Koelle DM. Expression Cloning for the Discovery of Viral Antigens and Epitopes Recognized by T-Cells. Methods (2003) 29:213–26. doi: 10.1016/s1046-2023(02)00344-4
30. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, et al. Activation-Induced Expression of CD137 Permits Detection, Isolation, and Expansion of the Full Repertoire of CD8+ T Cells Responding to Antigen Without Requiring Knowledge of Epitope Specificities. Blood (2007) 110:201–10. doi: 10.1182/blood-2006-11-056168
31. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L. Clearance of HSV-2 From Recurrent Genital Lesions Correlates With Infiltration of HSV-Specific Cytotoxic T Lymphocytes. J Clin Invest (1998) 101:1500–8. doi: 10.1172/JCI1758
32. Moretta A, Pantaleo G, Moretta L, Cerottini J-C, Mingari MC. Direct Demonstration of the Clonogenic Potential of Every Human Peripheral Blood T Cell. J Exp Med (1983) 157:743–54. doi: 10.1084/jem.157.2.743
33. Koelle DM, Chen HB, Gavin MA, Wald A, Kwok WW, Corey L. CD8 CTL From Genital Herpes Simplex Lesions: Recognition of Viral Tegument and Immediate Early Proteins and Lysis of Infected Cutaneous Cells. J Immunol (2001) 166:4049–58. doi: 10.4049/jimmunol.166.6.4049
34. Jing L, Laing KJ, Dong L, Russell RM, Barlow RS, Haas JG, et al. Extensive CD4 and CD8 T Cell Cross-Reactivity Between Alphaherpesviruses. J Immunol (2016) 196:2205–18. doi: 10.4049/jimmunol.1502366
35. Koelle DM, Schomogyi M, McClurkan C, Reymond SN, Chen HB. CD4 T-Cell Responses to Herpes Simplex Virus Type 2 Major Capsid Protein VP5: Comparison With Responses to Tegument and Envelope Glycoproteins. J Virol (2000) 74:11422–5. doi: 10.1128/jvi.74.23.11422-11425.2000
36. Johnston C, Zhu J, Jing L, Laing KJ, McClurkan CM, Klock A, et al. Virologic and Immunologic Evidence of Multifocal Genital Herpes Simplex Virus 2 Infection. J Virol (2014) 88:4921–31.
37. Jing L, Schiffer JT, Chong TM, Bruckner JJ, Davies DH, Felgner PL, et al. CD4 T-Cell Memory Responses to Viral Infections of Humans Show Pronounced Immunodominance Independent of Duration or Viral Persistence. J Virol (2013) 87:2617–27.
38. Nayak K, Jing L, Russell RM, Davies DH, Hermanson G, Molina DM, et al. Identification of Novel Mycobacterium Tuberculosis CD4 T-Cell Antigens via High Throughput Proteome Screening. Tuberculosis (Edinb) (2015) 95:275–87.
39. Ramchandani MS, Jing L, Russell RM, Tran T, Laing KJ, Magaret AS, et al. Viral Genetics Modulate Orolabial Herpes Simplex Virus Type 1 Shedding in Humans. J Infect Dis (2019) 219:1058–66.
40. Lefranc MP, Giudicelli V, Duroux P, Jabado-Michaloud J, Folch G, Aouinti S, et al. IMGT(R), the International ImMunoGeneTics Information System(R) 25 Years on. Nucleic Acids Res (2015) 43:D413–422.
41. Laing KJ, Magaret AS, Mueller DE, Zhao L, Johnston C, De Rosa SC, et al. Diversity in CD8(+) T Cell Function and Epitope Breadth Among Persons With Genital Herpes. J Clin Immunol (2010) 30:703–22.
42. Laing KJ, Russell RM, Dong L, Schmid DS, Stern M, Magaret A, et al. Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus. J Infect Dis (2015) 212(7):1022–31. doi: 10.1093/infdis/jiv164
43. Vita R, Overton JA, Greenbaum JA, Ponomarenko J, Clark JD, Cantrell JR, et al. The Immune Epitope Database (IEDB) 3.0. Nucleic Acids Res (2015) 43:D405–12.
44. Agyemang E, Magaret AS, Selke S, Johnston C, Corey L, Wald A. Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals. J Infect Dis (2018) 218(11):1691–9. doi: 10.1093/infdis/jiy372
45. Cunningham AL, Turner RR, Miller AC, Para MF, Merigan TC. Evolution of Recurrent Herpes Simplex Lesions: An Immunohistologic Study. J Clin Invest (1985) 75:226–33.
46. Yasukawa M, Kobayashi Y. Inhibition of Herpes Simplex Virus Replication In Vitro by Human Cytotoxic T Cell Clones and Natural Killer Cell Clones. J Gen Virol (1985) 66:2225–9. doi: 10.1099/0022-1317-66-10-2225
47. Boon T, van der Bruggen P. Human Tumor Antigens Recognized by T Lymphocytes. J Exp Med (1996) 183:725–9. doi: 10.1084/jem.183.3.725
48. Jing L, McCaughey SM, Davies DH, Chong TM, Felgner PL, De Rosa SC, et al. ORFeome Approach to the Clonal, HLA Allele-Specific CD4 T-Cell Response to a Complex Pathogen in Humans. J Immunol Methods (2009) 347:36–45. doi: 10.1016/j.jim.2009.05.011
49. Hanson DJ, Tsvetkova O, Rerolle GF, Greninger AL, Sette A, Jing L, et al. Genome-Wide Approach to the CD4 T-Cell Response to Human Herpesvirus 6b. J Virol (2019) 93(14):e00321–19. doi: 10.1128/JVI.00321-19
50. Dong L, Li P, Oenema T, McClurkan CL, Koelle DM. Public TCR Use by Herpes Simplex Virus-2-Specific Human CD8 CTLs. J Immunol (2010) 184:3063–71. doi: 10.4049/jimmunol.0903622
51. Koelle DM, Liu Z, McClurkan CL, Cevallos RC, Vieira J, Hosken NA, et al. Immunodominance Among Herpes Simplex Virus-Specific CD8 T Cells Expressing a Tissue-Specific Homing Receptor. Proc Natl Acad Sci USA (2003) 100:12899–904. doi: 10.1073/pnas.2131705100
52. Hensel MT, Peng T, Cheng A, De Rosa SC, Wald A, Laing KJ, et al. Selective Expression of CCR10 and CXCR3 by Circulating Human HSV-Specific CD8 T-Cells. J Virol (2017) 91:810–7. doi: 10.1128/JVI.00810-17
53. Koelle DM, Schomogyi M, Corey L. Antigen-Specific T Cells Localize to the Uterine Cervix in Women With Genital Herpes Simplex Virus Type 2 Infection. J Infect Dis (2000) 182:662–70. doi: 10.1086/315749
54. Koelle DM, Frank JM, Johnson ML, Kwok WW. Recognition of Herpes Simplex Virus Type 2 Tegument Proteins by CD4 T Cells Infiltrating Human Genital Herpes Lesions. J Virol (1998) 72:7476–83. doi: 10.1128/JVI.72.9.7476-7483.1998
55. Hosken N, McGowan P, Meier A, Koelle DM, Sleath P, Wegener F, et al. Diversity of the CD8+ T Cell Response to Herpes Simplex Virus Type 2 Proteins Among Persons With Genital Herpes. J Virol (2006) 80:5509–15. doi: 10.1128/JVI.02659-05
56. Koelle DM, Reymond SN, Chen H, Kwok WW, McClurkan C, Gyaltsong T, et al. Tegument-Specific, Virus-Reactive CD4 T Cells Localize to the Cornea in Herpes Simplex Virus Interstitial Keratitis in Humans. J Virol (2000) 74:10930–8. doi: 10.1128/JVI.74.23.10930-10938.2000
57. Campbell VL, Nguyen L, Snoey E, McClurkan CL, Laing KJ, Dong L, et al. Proteome-Wide Zika Virus CD4 T Cell Epitope and HLA Restriction Determination. Immunohorizons (2020) 4:444–53. doi: 10.4049/immunohorizons.2000068
58. Jing L, Ott M, Church CD, Kulikauskas RM, Ibrani D, Iyer JG, et al. Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8(+) T Cells Within Polyomavirus-Driven Merkel Cell Carcinomas. Cancer Immunol Res (2020) 8:648–59. doi: 10.1158/2326-6066.CIR-19-0647
59. Frank GM, Lepisto AJ, Freeman ML, Sheridan BS, Cherpes TL, Hendricks RL. Early CD4(+) T Cell Help Prevents Partial CD8(+) T Cell Exhaustion and Promotes Maintenance of Herpes Simplex Virus 1 Latency. J Immunol (2010) 184:277–86. doi: 10.4049/jimmunol.0902373
60. Isakov D, Dzutsev A, Belyakov IM, Berzofsky JA. Non-Equilibrium and Differential Function Between Intraepithelial and Lamina Propria Virus-Specific TCRalphabeta(+) CD8alphabeta(+) T Cells in the Small Intestinal Mucosa. Mucosal Immunol (2009) 2:450–61. doi: 10.1038/mi.2009.95
61. Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, et al. Safety and Immunogenicity of the Novel Tuberculosis Vaccine ID93 + GLA-SE in BCG-Vaccinated Healthy Adults in South Africa: A Randomised, Double-Blind, Placebo-Controlled Phase 1 Trial. Lancet Respir Med (2018) 6:287–98. doi: 10.1016/S2213-2600(18)30077-8
62. Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, et al. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Bladder Cancer. Cell (2020) 183:347–62.e324. doi: 10.1016/j.cell.2020.08.053
63. Laing KJ, Dong L, Sidney J, Sette A, Koelle DM. Immunology in the Clinic Review Series; Focus on Host Responses: T Cell Responses to Herpes Simplex Viruses. Clin Exp Immunol (2012) 167:47–58. doi: 10.1111/j.1365-2249.2011.04502.x
64. Collins N, Jiang X, Zaid A, Macleod BL, Li J, Park CO, et al. Skin CD4(+) Memory T Cells Exhibit Combined Cluster-Mediated Retention and Equilibration With the Circulation. Nat Commun (2016) 7:11514. doi: 10.1038/ncomms11514
65. Kiviat NB, Paavonen JA, Wolner-Hanssen P, Critchlow C, Stamm WE, Douglas J, et al. Histopathology of Endocervical Infection Caused by Chlamydia Trachomatis, Herpes Simplex Virus, Trichomonas Vaginalis, and Neisseria Gonorroeae. Hum Pathol (1990) 21:831–7. doi: 10.1016/0046-8177(90)90052-7
66. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, et al. Persistence of HIV-1 Receptor-Positive Cells After HSV-2 Reactivation is a Potential Mechanism for Increased HIV-1 Acquisition. Nat Med (2009) 15:886–92. doi: 10.1038/nm.2006
67. Ford ES, Sholukh AM, Boytz R, Carmack SS, Klock A, Phasouk K, et al. B Cells, Antibody-Secreting Cells, and Virus-Specific Antibodies Respond to Herpes Simplex Virus 2 Reactivation in Skin. J Clin Invest (2021) 131(9):e142088. doi: 10.1172/JCI142088
68. Johnston C, Gottlieb SL, Wald A. Status of Vaccine Research and Development of Vaccines for Herpes Simplex Virus. Vaccine (2016) 34:2948–52. doi: 10.1016/j.vaccine.2015.12.076
69. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al. Efficacy Results of a Trial of a Herpes Simplex Vaccine. New Engl J Med (2012) 366:34–43. doi: 10.1056/NEJMoa1103151
70. Bernstein DI, Bellamy AR, Hook EW, Levin MJ, Wald A, Ewell MG, et al. Epidemiology, Clinical Presentation, and Antibody Response to Primary Infection With Herpes Simplex Virus Type 1 and Type 2 in Young Women. Clin Infect Dis (2013) 56:344–51. doi: 10.1093/cid/cis891
71. Belshe RB, Heineman TC, Bernstein DI, Bellamy AR, Ewell M, van der Most R, et al. Correlate of Immune Protection Against HSV-1 Genital Disease in Vaccinated Women. J Infect Dis (2014) 209:828–36. doi: 10.1093/infdis/jit651
72. Awasthi S, Belshe RB, Friedman HM. Better Neutralization of Herpes Simplex Virus Type 1 (HSV-1) Than HSV-2 by Antibody From Recipients of GlaxoSmithKline HSV-2 Glycoprotein D2 Subunit Vaccine. J Infect Dis (2014) 210:571–5. doi: 10.1093/infdis/jiu177
73. Petro CD, Weinrick B, Khajoueinejad N, Burn C, Sellers R, Jacobs WR Jr., et al. HSV-2 DeltagD Elicits FcgammaR-Effector Antibodies That Protect Against Clinical Isolates. JCI Insight (2016) 1(12):e88529. doi: 10.1172/jci.insight.88529
74. Burn Aschner C, Loh LN, Galen B, Delwel I, Jangra RK, Garforth SJ, et al. HVEM Signaling Promotes Protective Antibody-Dependent Cellular Cytotoxicity (ADCC) Vaccine Responses to Herpes Simplex Viruses. Sci Immunol (2020) 5(50):eaax2454. doi: 10.1126/sciimmunol.aax2454
75. Long D, Skoberne M, Gierahn TM, Larson S, Price JA, Clemens V, et al. Identification of Novel Virus-Specific Antigens by CD4(+) and CD8(+) T Cells From Asymptomatic HSV-2 Seropositive and Seronegative Donors. Virology (2014) 464-465:296–311. doi: 10.1016/j.virol.2014.07.018
76. Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, et al. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. J Infect Dis (2018) 217:1750–60. doi: 10.1093/infdis/jiy095
77. Balachandran N, Bacchetti S, Rawls WE. Protection Against Lethal Challenge of Balb/c Mice by Passive Transfer of Monoclonal Antibodies to Five Glycoproteins of Herpes Simplex Virus Type 2. Infect Immun (1982) 37:1132–7. doi: 10.1128/iai.37.3.1132-1137.1982
78. Sullivan NL, Reuter-Monslow MA, Sei J, Durr E, Davis CW, Chang C, et al. Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified After Zostavax Vaccination in Humans. J Virol (2018) 92(14):e00269–18. doi: 10.1128/JVI.00269-18
79. Iwasaki A. Exploiting Mucosal Immunity for Antiviral Vaccines. Annu Rev Immunol (2016) 34:575–608. doi: 10.1146/annurev-immunol-032414-112315
80. Meignier B, Martin B, Whitley RJ, Roizman B. In Vivo Behaviour of Genetically Engineered Herpes Simplex Viruses R7017 and R7020. II. Studies in Immunocompetent and Immunocompromised Owl Monkeys (Aotus Trivirgatus). J Infect Dis (1990) 162:313–21. doi: 10.1093/infdis/162.2.313
81. Lo M, Zhu J, Hansen SG, Carroll T, Farr Zuend C, Nöel-Romas L, et al. Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 After Vaginal Inoculation of Rhesus Macaques. J Virol (2019) 93(2):e01574-18. doi: 10.1128/JVI.01574-18
82. Yim KC, Carroll CJ, Tuyama A, Cheshenko N, Carlucci MJ, Porter DD, et al. The Cotton Rat Provides a Novel Model to Study Genital Herpes Infection and to Evaluate Preventive Strategies. J Virol (2005) 79:14632–9. doi: 10.1128/JVI.79.23.14632-14639.2005
83. Awasthi S, Mahairas GG, Shaw CE, Huang ML, Koelle DM, Posavad C, et al. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens. J Virol (2015) 89:8497–509. doi: 10.1128/JVI.01089-15
84. Hill JM, Quenelle DC, Cardin RD, Vogel JL, Clement C, Bravo FJ, et al. Inhibition of LSD1 Reduces Herpesvirus Infection, Shedding, and Recurrence by Promoting Epigenetic Suppression of Viral Genomes. Sci Trans Med (2014) 6:265ra169. doi: 10.1126/scitranslmed.3010643
85. Lopez C. Genetics of Natural Resistance to Herpes Virus Infections in Mice. Nature (1975) 258:1352–3. doi: 10.1038/258152a0
86. Parr MB, Kepple L, McDermott MR, Drew MD, Bozzola JJ, Parr EL. A Mouse Model for Studies of Mucosal Immunity to Vaginal Infection by Herpes Simplex Virus Type 2. Lab Invest (1994) 70:369–80.
87. Hor JL, Whitney PG, Zaid A, Brooks AG, Heath WR, Mueller SN. Spatiotemporally Distinct Interactions With Dendritic Cell Subsets Facilitates CD4+ and CD8+ T Cell Activation to Localized Viral Infection. Immunity (2015) 43:554–65. doi: 10.1016/j.immuni.2015.07.020
88. Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon ML, et al. The Developmental Pathway for CD103(+)CD8+ Tissue-Resident Memory T Cells of Skin. Nat Immunol (2013) 14:1294–301. doi: 10.1038/ni.2744
89. Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, et al. Long-Lived Epithelial Immunity by Tissue-Resident Memory T (TRM) Cells in the Absence of Persisting Local Antigen Presentation. Proc Natl Acad Sci USA (2012) 109:7037–42. doi: 10.1073/pnas.1202288109
90. Park SL, Zaid A, Hor JL, Christo SN, Prier JE, Davies B, et al. Local Proliferation Maintains a Stable Pool of Tissue-Resident Memory T Cells After Antiviral Recall Responses. Nat Immunol (2018) 19(2):183–91. doi: 10.1038/s41590-017-0027-5
91. Alfonso-Dunn R, Turner AW, Jean Beltran PM, Arbuckle JH, Budayeva HG, Cristea IM, et al. Transcriptional Elongation of HSV Immediate Early Genes by the Super Elongation Complex Drives Lytic Infection and Reactivation From Latency. Cell Host Microbe (2017) 21:507–517.e505. doi: 10.1016/j.chom.2017.03.007
92. Schiffer JT, Swan DA, Prlic M, Lund JM. Herpes Simplex Virus-2 Dynamics as a Probe to Measure the Extremely Rapid and Spatially Localized Tissue-Resident T-Cell Response. Immunol Rev (2018) 285:113–33. doi: 10.1111/imr.12672
93. Roychoudhury P, Swan DA, Duke E, Corey L, Zhu J, Davé V, et al. Tissue-Resident T Cell-Derived Cytokines Eliminate Herpes Simplex Virus-2-Infected Cells. J Clin Invest (2020) 130:2903–19. doi: 10.1172/JCI132583
94. Smith CM, Belz GT, Wilson NS, Villadangos JA, Shortman K, Carbone FR, et al. Cutting Edge: Conventional CD8alpha(+) Dendritic Cells Are Preferentially Involved in CTL Priming After Footpad Infection With Herpes Simplex Virus-1. J Immunol (2003) 170:4437–40. doi: 10.4049/jimmunol.170.9.4437
95. Zhao X, Deak E, Soderberg K, Linehan M, Spezzano D, Zhu J, et al. Vaginal Submucosal Dendritic Cells, But Not Langerhans Cells, Induce Protective Th1 Responses to Herpes Simplex Virus-2. J Exp Med (2003) 197:153–62. doi: 10.1084/jem.20021109
96. Bosnjak L, Miranda-Saksena M, Koelle DM, Boadle RA, Jones CA, Cunningham AL. Herpes Simplex Virus Infection of Human Dendritic Cells Induces Apoptosis and Allows Cross-Presentation via Uninfected Dendritic Cells. J Immunol (2005) 174:2220–7. doi: 10.4049/jimmunol.174.4.2220
97. Su C, Zheng C. Herpes Simplex Virus 1 Abrogates the cGAS/STING-Mediated Cytosolic DNA-Sensing Pathway via Its Virion Host Shutoff Protein, Ul41. J Virol (2017) 91(6):e02414–16. doi: 10.1128/JVI.02414-16
98. Finnen RL, Hay TJ, Dauber B, Smiley JR, Banfield BW. The Herpes Simplex Virus 2 Virion-Associated Ribonuclease Vhs Interferes With Stress Granule Formation. J Virol (2014) 88:12727–39. doi: 10.1128/JVI.01554-14
99. Yao XD, Rosenthal KL. Herpes Simplex Virus Type 2 Virion Host Shutoff Protein Suppresses Innate dsRNA Antiviral Pathways in Human Vaginal Epithelial Cells. J Gen Virol (2011) 92:1981–93. doi: 10.1099/vir.0.030296-0
100. Taddeo B, Roizman B. The Virion Host Shutoff Protein (UL41) of Herpes Simplex Virus 1 Is an Endoribonuclease With a Substrate Specificity Similar to That of RNase A. J Virol (2006) 80:9341–5. doi: 10.1128/JVI.01008-06
101. Casto AM, Roychoudhury P, Xie H, Selke S, Perchetti GA, Wofford H, et al. Large, Stable, Contemporary Interspecies Recombination Events in Circulating Human Herpes Simplex Viruses. J Infect Dis (2020) 221:1271–9. doi: 10.1093/infdis/jiz199
102. Newman RM, Lamers SL, Weiner B, Ray SC, Colgrove RC, Diaz F, et al. Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. J Virol (2015) 89:8219–32. doi: 10.1128/JVI.01303-15
103. Lamers SL, Newman RM, Laeyendecker O, Tobian AA, Colgrove RC, Ray SC, et al. Global Diversity Within and Between Human Herpesvirus 1 and 2 Glycoproteins. J Virol (2015) 89:8206–18. doi: 10.1128/JVI.01302-15
104. Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, et al. Standard-Dose and High-Dose Daily Antiviral Therapy for Short Episodes of Genital HSV-2 Reactivation: Three Randomised, Open-Label, Cross-Over Trials. Lancet (London England) (2012) 379:641–7. doi: 10.1016/S0140-6736(11)61750-9
105. Watanabe R, Gehad A, Yang C, Scott LL, Teague JE, Schlapbach C, et al. Human Skin Is Protected by Four Functionally and Phenotypically Discrete Populations of Resident and Recirculating Memory T Cells. Sci Trans Med (2015) 7:279ra239. doi: 10.1126/scitranslmed.3010302
106. Kumar BV, Ma W, Miron M, Granot T, Guyer RS, Carpenter DJ, et al. Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites. Cell Rep (2017) 20:2921–34. doi: 10.1016/j.celrep.2017.08.078
107. Peng T, Phasouk K, Bossard E, Klock A, Jin L, Laing KJ, et al. Distinct Populations of Antigen Specific Tissue Resident CD8 T Cells in Human Cervix Mucosa. JCI Insight (2021) 6(15):e149950. doi: 10.1172/jci.insight.149950
108. Goodwin EC, DiMaio D. Repression of Human Papillomavirus Oncogenes in HeLa Cervical Carcinoma Cells Causes the Orderly Reactivation of Dormant Tumor Suppressor Pathways. Proc Natl Acad Sci USA (2000) 97:12513–8. doi: 10.1073/pnas.97.23.12513
109. Mercier-Letondal P, Marton C, Deschamps M, Ferrand C, Vauchy C, Chenut C, et al. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy. Hum Gene Ther (2018) 29:1202–12. doi: 10.1089/hum.2018.091
110. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, et al. Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: A Phase I Escalating-Dose Trial. J Virol (2008) 82:1968–79. doi: 10.1128/JVI.02343-07
111. Reeves E, Wood O, Ottensmeier CH, King EV, Thomas GJ, Elliott T, et al. HPV Epitope Processing Differences Correlate With ERAP1 Allotype and Extent of CD8(+) T-Cell Tumor Infiltration in OPSCC. Cancer Immunol Res (2019) 7:1202–13. doi: 10.1158/2326-6066.CIR-18-0498
112. Moss NJ, Magaret A, Laing KJ, Shaulov Kask A, Wang M, Mark KE, et al. Peripheral Blood CD4 T-Cell and pDC Reactivity to HSV-2 and pDC Number do Not Correlate With the Clinical or Virologic Severity of Recurrent Genital Herpes. J Virol (2012) 86(18):9952–63. doi: 10.1128/JVI.00829-12
Keywords: HSV-2, CD8, CD4, epitope, dendritic cell, female reproductive tract immunology
Citation: Koelle DM, Dong L, Jing L, Laing KJ, Zhu J, Jin L, Selke S, Wald A, Varon D, Huang M-L, Johnston C, Corey L and Posavad CM (2022) HSV-2-Specific Human Female Reproductive Tract Tissue Resident Memory T Cells Recognize Diverse HSV Antigens. Front. Immunol. 13:867962. doi: 10.3389/fimmu.2022.867962
Received: 01 February 2022; Accepted: 07 March 2022;
Published: 31 March 2022.
Edited by:
Richard D. Dix, Georgia State University, United StatesReviewed by:
Konstantin Kousoulas, Louisiana State University, United StatesHarvey Michael Friedman, University of Pennsylvania, United States
Copyright © 2022 Koelle, Dong, Jing, Laing, Zhu, Jin, Selke, Wald, Varon, Huang, Johnston, Corey and Posavad. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: David M. Koelle, viralimm@u.washington.edu